Revelle Aesthetics, based in Mountain View, CA, develops solutions to reduce cellulite centered on its FDA-cleared device Avéli. Avéli is indicated for long-term reduction in the appearance of cellulite, with clinical data demonstrating treatment benefits through one year of observation. The company received a $30 million growth capital commitment from Trinity Capital Inc. Revelle intends to use the funds to expand production capabilities and bolster the growth and expansion of its operations. Management plans to use proceeds to further penetrate the market, drive sales, and support marketing initiatives to reach a wider customer base. Caroline Van Hove serves as President and CEO. Revelle Aesthetics develops precision medical devices addressing women’s aesthetic needs with an initial focus on treating cellulite. Its first launched product, Avéli™, is FDA‑cleared for temporary reduction in the appearance of cellulite in the buttocks and thigh areas, with clinical data supporting benefits through three months of observation. The company emphasizes reliable outcomes for physicians and meaningful results for patients and targets a cash‑pay global cellulite market. Revelle plans to scale manufacturing, operations, and commercialization of Avéli and to invest in sales and marketing to raise consumer awareness and demand. Founded in 2018 and based in Mountain View, California, Revelle is privately backed by venture firms New Enterprise Associates and KCK Medtech. Management describes the business as operating in a competitive yet recession‑resilient medical aesthetics market.

Total raised

$55M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2023